In a phase 1 trial, patients with relapsed/refractory B-cell NHL and CLL were treated with tandem bispecific CAR-T cells targeting CD20 and CD19 (LV20.19) [76]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.